KaushalParikhMD

Oncology • Rochester, MN

Hematologic Oncology

Physician

Join to view full profile

Dr. Parikh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Parikh's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2019
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
Westchester Medical CenterResidency, Internal Medicine, 2012 - 2015
Topiwala National Medical CollegeClass of 2011

Certifications & Licensure

MN State Medical License 2022 - 2025
NJ State Medical License 2019 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Targetable molecular algorithm and training platform development for the treatment of non-small cell lung cancer.
Krithika Bhuvaneshwar, Chul Kim, Kaushal Parikh, Joshua E Reuss, Camelia Bencheqroun
JAMIA Open. 2024-12-01
4 citations
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positi...
Kaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, Aaron S Mansfield, Mohamed Shanshal
Journal of Thoracic Oncology. 2024-11-01
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Amin H Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances Shepherd, Elio Adib
Journal of Thoracic Oncology. 2024-09-10

Lectures

Low nationwide utilization of adjuvant chemotherapy (AC) in elderly patients with localized non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019
Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction.
2019 ASCO Annual Meeting - 6/1/2019
A nationwide analysis of palliative care service utilization in hospitalized metastatic cancer patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018